Où achat cialis sans ordonnance et acheter viagra en France.
Drug combination shows promise for newly diagnosed blood cancer patients, study finds
Cell Therapy Summit EU
CTS Europe The Leadership Gathering for Cell therapy Executives
98% Thyroid Disease Cured
100% Natural Herbs, with TGA, GMP, SGS. Thousands of recovery cases!
M ultiple Sclerosis
Recovery for MS in China by herbal tea, massage, acupuncture.
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer
Brain Imaging Shows Video Game Aptitude
Patients, Study Finds
Science Video News
ScienceDaily (Dec. 11, 2010)
— A new three-drug
Ads by Google
combination used to treat the blood cancer multiple
Heate d Che mo
myeloma may be effective as a front-line therapy for
newly diagnosed patients, according to a study led
by the University of Michigan Comprehensive Cancer www .aldlife .org
Ocular Oncologists Inject Drug Into Eye To Starve
Urologists Use Optics, Chemistry to Catch Small
Health & Medicine
Drug Discovery Conference
Molecular Biologists Devise Strategy To Starve
New Sequencing Report
The Theory of Everything
Some physicists think the mind is at the heart
American Society of HematologyAnnual Meeting and Exposition.
Hodgkin's lymphoma to deliver everything we expected and
Aggressive Blood Cancer: Clinical Trial of
Clinical Research in AZ
Lenalidomide Plus Dexamethasone Followed
by Autologous Stem Cell Transplantation
(ASCT) in Multiple Myeloma
(Dec. 7, 2010) — A
new transplantation technique, which uses a
Head Covering - HeadBands
patient's own adult stem cells, has been a first-line
program at the University of Michigan Comprehensive Cancer
cotton silk wool hat for girl/women Fashion
treatment for patients who are newly diagnosed with
certain blood cancers. Multiple myeloma is a .
The study, which still is accruing participants, has enrolled 31
people to date. All patients responded to this combination,
Multiple Myeloma Patients Experience High
measured by at least a 50 percent reduction of the disease,
Response Rate With New 3-Drug Combination
and the disease was completely or nearly eliminated in a
(Dec. 7, 2009) — A new three-drug combination has
shown in a phase 1/2 clinical trial that it is a "highly
Responses were rapid, and the depth of response continued to
effective regimen" in the treatment of patients newly
improve with additional treatment. Of patients who completed
diagnosed with multiple myeloma, a cancer of white
eight cycles of therapy, more than two-thirds achieved a
complete response, meaning they showed little or no signs of
Three-Drug Combination 'Extremely Promising'
cancer. These response rates appear to be higher than those
As First-Line Therapy For Multiple Myeloma
achieved by the best current regimens in newly diagnosed
bortezomib (Velcade) and two other drugs is
After a median follow-up of six months, all patients were alive
showing a very high response rate in patients newly
with no progression of their cancer.
diagnosed with multiple myeloma, a team headed
by Dana-Farber Cancer Institute . > read more
Researchers found that the three-drug combination, called
CRd, was well-tolerated, with few serious side effects. Most
Multiple Myeloma Clinical Trial Shows Distinct
notably, peripheral neuropathy -- which is marked by
Survival Benefit With Lower Dose Of Steroids
numbness or tingling of the fingers and toes and can cause
(Dec. 13, 2007) — Results of Eastern Cooperative
significant pain, depending on the severity -- was infrequent and
Oncology Group Phase III clinical trial E4A03, for
mild with this treatment. This side effect typically limits
multiple myeloma show significantly better overall
extended use of currently available multiple myeloma
treatments and is often the reason patients discontinue a
dexamethasone therapy . > read more
In Othe r Ne ws .
New Therapeutic Options For Newly Diagnosed
The study also included patients who were eligible for a stem
Multiple Myeloma Patients
(Dec. 11, 2007) —
cell transplant. The researchers found that these patients were
Mayo Clinic researchers have presented results of a
able to remain on CRd treatment and achieved responses
phase II trial of myeloma induction therapy -- a first
similar to or better than those observed after a stem cell
step therapy designed to reduce cancer cells
transplant. This outcome delayed the need for a stem cell
numbers -- with cyclophosphamide, bortezomib, .
"Newly diagnosed myeloma is most sensitive to treatment. A
Ads by Google
great response in the initial phase of treatment is critical
because it projects how long patients will remain in remission,
Single Cell PCR
as well as their overall survival. Patients have a better chance
of living longer if their response to initial treatment is better,"
says Jakubowiak, associate professor of internal medicine at
Carfilzomib has recently emerged as an important drug in
treatment of multiple myeloma. It has previously been tested
as a single-agent in patients who have exhausted all available
treatment options and in relapsed disease. Currently, a Phase
III trial is ongoing looking at CRd compared with lenalidomide
and low dose dexamethasone alone for patients with relapsed
Multiple myeloma statistics:
Renal Cell Carcinoma
20,180 Americans will be diagnosed with multiple myeloma
Giffords doing well after weekend surgeries:
this year and 10,650 will die from the disease, according to the
Dominik Dytfeld, M.D., Ph.D., Tara B. Anderson, Brian
Copyright Reuters 2008. See Restrictions.
Nordgren, Daniel Lebovic, M.D., Kent Griffith, Melissa Hill,Colleen Harvey, all from U-M; Sundar Jagannath, M.D., Mt.
Sinai Medical Center; David H. Vesole, M.D., Ph.D.,
Hackensack University Medical Center; Keith Stockerl-Goldstein, M.D., and Ravi Vij, M.D., Washington University
Get the latest science news with our free email
School of Medicine, St. Louis; Akari Dollard, Dana Farber
newsletters, updated daily and weekly. Or view
Cancer Institute; Robert Ott and Susan L. Kelley, M.D.,
hourly updated newsfeeds in your RSS reader:
Multiple Myeloma Research Consortium; Jennifer Barrickman,
Celgene Corp.; and Michael Kauffman, M.D., Onyx
Multiple Myeloma Research Consortium, Onyx
Tell us what you think of ScienceDaily -- we
Pharmaceuticals Inc., Celgene Corporation and the U-M
welcome both positive and negative comments.
Have any problems using the site? Questions?
The above story is reprinted (with editorial adaptations by
staff) from materials provided by University of
Michigan Health System
Need to cite this story in your essay, paper, or report? Use
University of Michigan Health System (2010,December 11). Drug combination shows
promise for newly diagnosed blood cancerpatients, study finds. ScienceDaily
. RetrievedJanuary 18, 2011, from
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical
advice, diagnosis or treatment. Views expressed here do not
necessarily reflect those of ScienceDaily or its staff.
Number of stories in archives: 96,676
Enter a keyword or phrase to search ScienceDaily's archives for related news topics, the latest news stories, reference articles, science videos, images, and books.
Copyright 1995-2010 ScienceDaily LLC — All rights reserved — Contact:
Note: This web site is not intended to provide medical advice, diagnosis or treatment.
Part of the iVillage Your Total Health Network
Climate change and its impact on health in Bangladesh Climate change affects human health both directly and indirectly. People are exposed This background paper was prepared for a workshop on Climate Change and Health in (temperature, precipitation, sea-level rise and Bangladesh, held on 19–20 November 2007 more frequent extreme events) and indirectly through changes in the quality of wa
HOBO® U22 Water Temp Pro v2 (Part # U22-001) The HOBO Water Temp Pro v2 logger is designed with a durable, streamlined, UV-stable case for extended deployments measuring temperature in fresh or salt water. The small size of the logger allows it to be easily mounted and/or hidden in the field. It is waterproof up to 120 m (400 feet) and rugged enough to withstand years of use, even in